Armistice Capital
$3.6B 13F equity value
419 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Armistice Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| MDGL | MADRIGAL PHARMACEUTICALS INC | 288,000 | $155M | 4.3% |
| SUPN | SUPERNUS PHARMACEUTICALS | 2,646,201 | $123M | 3.4% |
| CYTK | CYTOKINETICS INC | 1,201,342 | $102M | 2.8% |
| INCY | INCYTE CORP | 900,005 | $102M | 2.8% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 535,838 | $90M | 2.5% |
| TVTX | TRAVERE THERAPEUTICS INC | 1,572,539 | $89M | 2.5% |
| AGIO | AGIOS PHARMACEUTICALS INC | 2,400,000 | $89M | 2.5% |
| PTCT | PTC THERAPEUTICS INC | 1,071,395 | $87M | 2.4% |
| UNH | UNITEDHEALTH GROUP INC | 183,000 | $76M | 2.1% |
| FRPT | FRESHPET INC | 1,260,702 | $75M | 2.1% |
Track Armistice Capital's 13F portfolio: $3.6B in reported holdings, 419 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}